Patents by Inventor Anke Klippel
Anke Klippel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8933215Abstract: The present invention is related to a ribonucleic acid comprising a double stranded structure whereby the double-stranded structure comprises a first strand and a second strand, whereby the first strand comprises a first stretch of contiguous nucleotides and whereby said first stretch is at least partially complementary to a target nucleic acid, and the second strand comprises a second stretch of contiguous nucleotides whereby said second stretch is at least partially identical to a target nucleic acid, and whereby the double stranded structure is blunt ended.Type: GrantFiled: December 3, 2012Date of Patent: January 13, 2015Assignee: Silence Therapeutics Aktiengesellschaft (AG)Inventors: Klaus Giese, Jörg Kaufmann, Anke Klippel-Giese
-
Publication number: 20130065928Abstract: Disclosed is the discovery that the mTORC2 complex plays a role in the regulation of PKN3 phosphorylation at the turn motif threonine; and the use of the phosphorylation status of the turn motif threonine of PKN3 as a biomarker. In some embodiments, the phosphorylation status of the turn motif threonine of PKN3 is determined using an antibody that specifically binds to the turn motif threonine of a PKN3 protein, such as an anti-phosphoT860 antibody. In some embodiments, the invention relates to methods for screening compounds that have cancer therapeutic potential, methods for diagnosing cancer, methods for determining the prognosis of a patient suffering from cancer, methods for stratifying patients in a clinical trial, methods for treating a patient suffering from cancer, and methods for determining the effectiveness of a particular treatment regimen.Type: ApplicationFiled: April 2, 2011Publication date: March 14, 2013Applicant: WYETH LLCInventors: Anke Klippel-Giese, Keziban Unsal-Kacmaz
-
Patent number: 8324370Abstract: The present invention is related to a ribonucleic acid comprising a double stranded structure whereby the double-stranded structure comprises a first strand and a second strand, whereby the first strand comprises a first stretch of contiguous nucleotides and whereby said first stretch is at least partially complementary to a target nucleic acid, and the second strand comprises a second stretch of contiguous nucleotides whereby said second stretch is at least partially identical to a target nucleic acid, and whereby the double stranded structure is blunt ended.Type: GrantFiled: January 7, 2011Date of Patent: December 4, 2012Assignee: Silence Therapeutics Aktiengesellschaft (AG)Inventors: Klaus Giese, Jörg Kaufmann, Anke Klippel-Giese
-
Publication number: 20120171220Abstract: The present invention is related to use of protein kinase N beta or a fragment or derivative thereof as a downstream target of the PI 3-kinase pathway, preferably as a downstream drug target of the PI 3-kinase pathway.Type: ApplicationFiled: February 9, 2012Publication date: July 5, 2012Applicant: Silence Therapeutics Aktiengesellschaft (AG)Inventors: ANKE KLIPPEL-GIESE, Jörg Kaufmann
-
Publication number: 20120100561Abstract: Disclosed are compositions comprising and methods of using a novel macromolecular assembly comprising PKN3, PDK1 and RhoC (PPRC complex). The PPRC complex was shown to have kinase activity and was found in cells of high malignancy potential, such as particularly aggressive cancers. In some aspects, the invention provides methods for screening compounds that have cancer therapeutic potential, methods for diagnosing aggressive cancer, methods for determining the prognosis of a patient suffering from cancer, methods for stratifying patients in a clinical trial or determining the effectiveness of a particular treatment regimen, polypeptides that modulate the formation of the PPRC complex, and kits comprising one or more components of the PPRC complex.Type: ApplicationFiled: March 12, 2010Publication date: April 26, 2012Inventors: Anke Klippel-Giese, Keziban Unsal-Kacmaz
-
Publication number: 20110118456Abstract: The present invention is related to a ribonucleic acid comprising a double stranded structure whereby the double-stranded structure comprises a first strand and a second strand, whereby the first strand comprises a first stretch of contiguous nucleotides and whereby said first stretch is at least partially complementary to a target nucleic acid, and the second strand comprises a second stretch of contiguous nucleotides whereby said second stretch is at least partially identical to a target nucleic acid, and whereby the double stranded structure is blunt ended.Type: ApplicationFiled: January 7, 2011Publication date: May 19, 2011Applicant: SILENCE THERAPEUTICS AGInventors: Klaus Giese, Jörg Kaufmann, Anke Klippel-Giese
-
Patent number: 7893245Abstract: The present invention is related to a ribonucleic acid comprising a double stranded structure whereby the double-stranded structure comprises a first strand and a second strand, whereby the first strand comprises a first stretch of contiguous nucleotides and whereby said first stretch is at least partially complementary to a target nucleic acid, and the second strand comprises a second stretch of contiguous nucleotides whereby said second stretch is at least partially identical to a target nucleic acid, and whereby the double stranded structure is blunt ended.Type: GrantFiled: August 28, 2008Date of Patent: February 22, 2011Assignee: Silence Therapeutics Aktiengesellschaft (AG)Inventors: Klaus Giese, Jörg Kaufmann, Anke Klippel-Giese
-
Publication number: 20110008320Abstract: The present invention is related to use of protein kinase N beta or a fragment or derivative thereof as a downstream target of the PI 3-kinase pathway, preferably as a downstream drug target of the PI 3-kinase pathway.Type: ApplicationFiled: February 26, 2010Publication date: January 13, 2011Applicant: SILENCE THERAPEUTICS AKTIENGESELLSCHAFTInventors: Anke Klippel-Giese, Jörg Kaufmann
-
Publication number: 20100285038Abstract: The present invention is related to a nucleic acid coding for a factor involved in a biological process, whereby the process is a PI 3-kinase pathway regulated process, preferably a process selected from the group comprising glucose metabolism, amino acid and glucose deprivation processes, diabetes, wound healing, stress response, apoptosis, metastasis, tumorigenesis, cell migration, cell motility in extracellular matrix and cell growth in extracellular matrix, and the factor is a polypeptide comprising an amino acid sequence according to SEQ ID. NO. 1 or a polypeptide having a sequence according to databank entries gi 9506687 or NP_061931, preferably NP_061931.1.Type: ApplicationFiled: March 10, 2010Publication date: November 11, 2010Inventors: ANKE KLIPPEL-GIESE, JOERG KAUFMANN, ROLF SCHWARZER
-
Patent number: 7713943Abstract: The present invention is related to use of protein kinase N beta or a fragment or derivative thereof as a downstream target of the PI 3-kinase pathway, preferably as a downstream drug target of the PI 3-kinase pathway.Type: GrantFiled: August 14, 2003Date of Patent: May 11, 2010Assignee: Silence Therapeutics Aktiengesellschaft (AG)Inventors: Anke Klippel-Giese, Jörg Kaufmann
-
Publication number: 20090186845Abstract: The present invention is related to a ribonucleic acid comprising a double stranded structure whereby the double-stranded structure comprises a first strand and a second strand, whereby the first strand comprises a first stretch of contiguous nucleotides and whereby said first stretch is at least partially complementary to a target nucleic acid, and the second strand comprises a second stretch of contiguous nucleotides whereby said second stretch is at least partially identical to a target nucleic acid, and whereby the double stranded structure is blunt ended.Type: ApplicationFiled: August 28, 2008Publication date: July 23, 2009Applicant: SILENCE THERAPEUTICS AGInventors: KLAUS GIESE, Jorg Kaufmann, Anke Klippel-Giese
-
Patent number: 7452987Abstract: The present invention is related to a ribonucleic acid comprising a double stranded structure whereby the double-stranded structure comprises a first strand and a second strand, whereby the first strand comprises a first stretch of contiguous nucleotides and whereby said first stretch is at least partially complementary to a target nucleic acid, and the second strand comprises a second stretch of contiguous nucleotides whereby said second stretch is at least partially identical to a target nucleic acid, and whereby the double stranded structure is blunt ended.Type: GrantFiled: August 5, 2003Date of Patent: November 18, 2008Assignee: Silence Therapeutics Aktiengesellschaft (AG)Inventors: Klaus Giese, Jörg Kaufmann, Anke Klippel-Giese
-
Publication number: 20060240022Abstract: The present invention is related to a nucleic acid coding for a factor involved in a biological process, whereby the process is a PI 3-kinase pathway regulated process, preferably a process selected from the group comprising glucose metabolism, amino acid and glucose deprivation processes, diabetes, wound healing, stress response, apoptosis, metastasis, tumorigenesis, cell migration, cell mobility in extracellular matrix and cell growth in extracellular matrix, and the factor is a polypeptide comprising an amino acid sequence according to SEQ ID. NO. 1 or a polypeptide having a sequence according to databank entries gi 9506687 or NP_061931, preferably NP_061931.1.Type: ApplicationFiled: October 20, 2003Publication date: October 26, 2006Applicant: ATUGEN AGInventors: Anke Klippel-Giese, Joerg Kaufmann, Rolf Schwarzer
-
Publication number: 20060228346Abstract: The invention provides a method of producing a constitutively active phosphatidylinositol 3-kinase (PI 3-kinase) comprising the catalytic p110 subunit covalently attached at the N-terminus to the iSH2 region of the regulatory subunit, p85. The invention discloses one form of the constitutively active kinase, p110*, which functions independently of growth factor stimulation. Expression vectors encoding a constitutively active PI 3-kinase and cells containing such expression vectors are provided. The invention also provides methods of using the constitutively active phosphatidylinositol 3-kinase to generate phosphoinositides, to identify cellular target proteins and associating molecules of PI 3-kinase, to screen for inhibitors of PI 3-kinase activity and to treat certain diseases, in particular, proliferative diseases. Kits comprising the constitutively active kinase are also provided.Type: ApplicationFiled: September 26, 2001Publication date: October 12, 2006Applicant: The Regents of the University of CaliforniaInventors: Anke Klippel, Lewis Williams
-
Publication number: 20040180351Abstract: The present invention is related to a ribonucleic acid comprising a double stranded structure whereby the double-stranded structure comprises a first strand and a second strand, whereby the first strand comprises a first stretch of contiguous nucleotides and whereby said first stretch is at least partially complementary to a target nucleic acid, and the second strand comprises a second stretch of contiguous nucleotides whereby said second stretch is at least partially identical to a target nucleic acid, and whereby the double stranded structure is blunt ended.Type: ApplicationFiled: August 5, 2003Publication date: September 16, 2004Applicant: Atugen AGInventors: Klaus Giese, Jorg Kaufmann, Anke Klippel-Giese
-
Publication number: 20040106569Abstract: The present invention is related to use of protein kinase N beta or a fragment or derivative thereof as a downstream target of the PI 3-kinase pathway, preferably as a downstream drug target of the PI 3-kinase pathway.Type: ApplicationFiled: August 14, 2003Publication date: June 3, 2004Applicant: Atugen AGInventors: Anke Klippel-Giese, Jorg Kaufmann
-
Publication number: 20040091898Abstract: Polynucleotide constructs encoding growth factor independent catalytically active membrane targeted PI 3-kinase mutants useful for therapeutic and research purposes are described. In addition, a method for using the polynucleotide constructs to screen for inhibitors of PI 3-kinase, a method for making 3′ phosphorylated inositol phospholipids, methods of reducing cell death after trauma, and methods of overcoming insulin resistance are described.Type: ApplicationFiled: June 23, 2003Publication date: May 13, 2004Inventors: Anke Klippel, W. Michael Kavanaugh, Stephen D. Harrison, Lewis T. Williams
-
Patent number: 6613956Abstract: Polynucleotide constructs encoding growth factor independent catalytically active membrane targeted PI 3-kinase mutants useful for therapeutic and research purposes are described. In addition, a method for using the polynucleotide constructs to screen for inhibitors of PI 3-kinase, a method for making 3′ phosphorylated inositol phospholipids, methods of reducing cell death after trauma, and methods of overcoming insulin resistance are described.Type: GrantFiled: April 2, 1997Date of Patent: September 2, 2003Assignee: Chiron CorporationInventors: Anke Klippel, W. Michael Kavanaugh, Stephen D. Harrison, Lewis T. Williams
-
Publication number: 20030135033Abstract: The present invention is related to a compound, preferably 14 to 30 nucleobases, preferably 17 to 23 nucleobases and more preferably 17 to 21 nucleobases in length, targeted to a nucleic acid whereby the nucleic acid is heterogeneous nuclear RNA (hnRNA).Type: ApplicationFiled: January 6, 2003Publication date: July 17, 2003Inventors: Anke Klippel-Giese, Jorg Kaufmann, Klaus Giese
-
Patent number: 6300111Abstract: The invention provides a method of producing a constitutively active phosphatidylinositol 3-kinase (PI 3-kinase) comprising the catalytic p110 subunit covalently attached at the N-terminus to the iSH2 region of the regulatory subunit, p85. The invention discloses one form of the constitutively active kinase, p110*, which functions independently of growth factor stimulation. Expression vectors encoding a constitutively active PI 3-kinase and cells containing such expression vectors are provided. The invention also provides methods of using the constitutively active phosphatidylinositol 3-kinase to generate phosphoinositides, to identify cellular target proteins and associating molecules of PI 3-kinase, to screen for inhibitors of PI 3-kinase activity and to treat certain diseases, in particular, proliferative diseases. Kits comprising the constitutively active kinase are also provided.Type: GrantFiled: March 10, 1999Date of Patent: October 9, 2001Assignee: The Regents of the University of CaliforniaInventors: Anke Klippel, Lewis T. Williams